DE69732984T2 - Aminoindanderivate - Google Patents

Aminoindanderivate Download PDF

Info

Publication number
DE69732984T2
DE69732984T2 DE69732984T DE69732984T DE69732984T2 DE 69732984 T2 DE69732984 T2 DE 69732984T2 DE 69732984 T DE69732984 T DE 69732984T DE 69732984 T DE69732984 T DE 69732984T DE 69732984 T2 DE69732984 T2 DE 69732984T2
Authority
DE
Germany
Prior art keywords
compound according
propargyl
methyl
dementia
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69732984T
Other languages
German (de)
English (en)
Other versions
DE69732984D1 (de
Inventor
Michael Chorev
Tamar Goren
Yacov Herzig
Jeffrey Sterling
Marta Weinstock-Rosin
B. Moussa YOUDIM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Technion Research and Development Foundation Ltd
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Teva Pharmaceutical Industries Ltd
Technion Research and Development Foundation Ltd
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL11985396A external-priority patent/IL119853A0/xx
Priority claimed from IL12051097A external-priority patent/IL120510A0/xx
Application filed by Teva Pharmaceutical Industries Ltd, Technion Research and Development Foundation Ltd, Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Teva Pharmaceutical Industries Ltd
Publication of DE69732984D1 publication Critical patent/DE69732984D1/de
Application granted granted Critical
Publication of DE69732984T2 publication Critical patent/DE69732984T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/56—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/58—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/02—Monothiocarbamic acids; Derivatives thereof
    • C07C333/04—Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Centrifugal Separators (AREA)
DE69732984T 1996-12-18 1997-12-18 Aminoindanderivate Expired - Lifetime DE69732984T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IL11985396 1996-12-18
IL11985396A IL119853A0 (en) 1996-12-18 1996-12-18 Aminoindan derivatives
IL12051097 1997-03-24
IL12051097A IL120510A0 (en) 1997-03-24 1997-03-24 Phenylethylamine derivatives
PCT/US1997/024155 WO1998027055A1 (en) 1996-12-18 1997-12-18 Aminoindan derivatives

Publications (2)

Publication Number Publication Date
DE69732984D1 DE69732984D1 (de) 2005-05-12
DE69732984T2 true DE69732984T2 (de) 2006-02-16

Family

ID=26323338

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69738275T Expired - Lifetime DE69738275T2 (de) 1996-12-18 1997-12-18 Aminoindanderivate
DE69732984T Expired - Lifetime DE69732984T2 (de) 1996-12-18 1997-12-18 Aminoindanderivate

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69738275T Expired - Lifetime DE69738275T2 (de) 1996-12-18 1997-12-18 Aminoindanderivate

Country Status (13)

Country Link
US (4) US6303650B1 (enExample)
EP (2) EP0966435B1 (enExample)
JP (1) JP4222632B2 (enExample)
AT (2) ATE377585T1 (enExample)
AU (1) AU5726898A (enExample)
CA (1) CA2275425C (enExample)
DE (2) DE69738275T2 (enExample)
DK (1) DK0966435T3 (enExample)
ES (1) ES2241064T3 (enExample)
HU (1) HU229507B1 (enExample)
IL (1) IL130528A (enExample)
PT (1) PT966435E (enExample)
WO (1) WO1998027055A1 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE377585T1 (de) * 1996-12-18 2007-11-15 Teva Pharma Aminoindanderivate
DE69921815T2 (de) * 1998-06-03 2005-11-10 Nissan Chemical Industries, Ltd. Indanderivate
JP2003512426A (ja) 1999-10-27 2003-04-02 テバ ファーマシューティカル インダストリーズ リミティド 双極性気分障害における躁病の治療のための１−アミノインダンの使用。
WO2003072055A2 (en) * 2002-02-27 2003-09-04 Teva Pharmaceutical Industries, Ltd. Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective mao inhibitors
US20040010038A1 (en) * 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
JP4757024B2 (ja) * 2002-11-07 2011-08-24 テクニオン リサーチ アンド ディベラップメント ファウンデイション リミテッド 神経保護鉄キレート剤及びそれを含む医薬組成物
CA2547053C (en) 2003-11-25 2014-05-27 Technion Research & Development Foundation Ltd. Compositions and methods for treatment of cardiovascular disorders and diseases
US8097608B2 (en) 2003-11-25 2012-01-17 Technion Research And Development Foundation Ltd. Methods for treatment of cardiovascular disorders and diseases
JP2005232148A (ja) * 2004-02-03 2005-09-02 Technion Research & Development Foundation Ltd 神経保護剤としてプロパルギルアミンの使用
EP1574498A1 (en) 2004-02-19 2005-09-14 PPG-Sipsy Process for the synthesis of substituted alpha-aminoindan derivatives
EP1778196A4 (en) * 2004-07-26 2008-12-17 Teva Pharma PHARMACEUTICAL DOSAGES CONTAINING RASAGILINE
WO2006014968A2 (en) * 2004-07-27 2006-02-09 Teva Pharmaceutical Industries, Ltd. Propargyl nitroxydes and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders
US7262326B2 (en) 2004-09-08 2007-08-28 Teva Pharmaceuticals Industries Ltd. Process for the synthesis of indanylamine or aminotetralin derivatives and novel intermediates
ES2420404T3 (es) * 2005-02-17 2013-08-23 Teva Pharmaceutical Industries Ltd. Terapia de combinación con acetato de glatiramero y rasagilina para el tratamiento de esclerosis múltiple
EP1851188A1 (en) 2005-02-22 2007-11-07 Teva Pharmaceutical Industries Limited Improved process for the synthesis of enantiomeric indanylamine derivatives
AU2006216696B2 (en) 2005-02-23 2011-08-18 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
JP2008531571A (ja) * 2005-02-24 2008-08-14 テバ ファーマシューティカル インダストリーズ リミティド 酒石酸ラドスチジルの結晶、その製造方法、および医薬組成物
WO2006091836A1 (en) 2005-02-24 2006-08-31 Teva Pharmaceutical Industries, Ltd. Formulations of ladostigil tartrate
WO2006130726A2 (en) * 2005-06-01 2006-12-07 Teva Pharmaceutical Industries, Ltd. Use of ladostigil for the treatment of multiple sclerosis
NZ564130A (en) * 2005-06-02 2009-12-24 Jenrin Discovery N-propargyl-1-aminoindan compounds useful for treating obesity
US7539261B2 (en) * 2005-08-22 2009-05-26 Nec Laboratories America, Inc. Multi-layer coded modulation for non-ergodic block fading channels
US20070088082A1 (en) * 2005-09-28 2007-04-19 Judith Aronhime Polymorphic forms of ladostigil tartrate
WO2007038677A2 (en) * 2005-09-28 2007-04-05 Teva Pharmaceutical Industries Ltd. Methods for preparation of ladostigil tartrate crystalline form a1
US8263655B2 (en) * 2005-10-06 2012-09-11 Technion Research And Development Foundation Ltd Methods for treatment of renal failure
US20070238893A1 (en) * 2005-11-04 2007-10-11 Lee Boulton Asymmetric hydrogenation of acyl enamides
US20070238895A1 (en) * 2005-11-07 2007-10-11 Lee Boulton N-protected aminoindanes and methods of their preparation
JP2009521402A (ja) * 2005-11-17 2009-06-04 テバ ファーマシューティカル インダストリーズ リミティド プロパルギル化アミノインダンの分離のための方法
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
AU2006326642B2 (en) * 2005-12-09 2012-05-03 Technion Research And Development Foundation Ltd. Use of low-dose ladostigil for neuroprotection
US20070135518A1 (en) * 2005-12-09 2007-06-14 Marta Weinstock-Rosin Use of low-dose ladostigil for neuroprotection
EP1991214B1 (en) 2006-02-21 2015-08-05 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
TW200744576A (en) 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
US20070232691A1 (en) * 2006-03-31 2007-10-04 Tamar Goren Use of ladostigil for the treatment of schizophrenia
US8946300B2 (en) 2006-04-03 2015-02-03 Teva Pharmaceutical Industries, Ltd. Use of rasagilline for the treatment of restless legs syndrome
EP1892233A1 (de) * 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
ATE528989T1 (de) * 2006-12-14 2011-11-15 Teva Pharma Kristalline feste rasagilin-base
US7547806B2 (en) 2006-12-14 2009-06-16 Teva Pharmaceutical Industries, Ltd. Tannate salt of rasagiline
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
NZ586025A (en) * 2008-01-11 2012-08-31 Teva Pharma Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate
WO2009151594A1 (en) * 2008-06-10 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
JP2011522892A (ja) * 2008-06-13 2011-08-04 テバ ファーマシューティカル インダストリーズ リミティド パーキンソン病緩和のためのラサギリン
JP2011525489A (ja) * 2008-06-19 2011-09-22 テバ ファーマシューティカル インダストリーズ リミティド ラサリジン塩基の精製方法
EP2299992A4 (en) 2008-06-19 2015-10-21 Teva Pharma PROCESS FOR THE PREPARATION AND DRYING OF A SOLID RASAGILINE BASE
US20100189788A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline base formulation
HRP20140845T1 (hr) 2009-07-09 2014-11-07 Ratiopharm Gmbh Soli rasagilina i farmaceutski pripravci od njih
US9943489B2 (en) 2010-02-03 2018-04-17 Pharmatwob Ltd. Extended release formulations of rasagiline and uses thereof
RU2013108256A (ru) 2010-07-27 2014-09-10 Тева Фармасьютикал Индастриз Лтд. Дисперсии цитрата разагилина
RU2587330C2 (ru) 2010-07-27 2016-06-20 Тева Фармасьютикал Индастриз Лтд. Применение разагилина для лечения обонятельной дисфункции
US9339469B2 (en) 2011-10-10 2016-05-17 Teva Pharmaceutical Industries, Ltd. R(+)-N-methyl-propargyl-aminoindan
EA201490761A1 (ru) 2011-10-10 2014-11-28 Тева Фармасьютикал Индастриз Лтд. R(+)-n-формилпропаргиламиноиндан
CN104379142B (zh) * 2012-02-12 2018-02-13 耶路撒冷希伯来大学伊森姆研究发展有限公司 用于免疫调节的拉多替吉治疗
JP2015529196A (ja) 2012-08-17 2015-10-05 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンの非経口製剤
CN121001985A (zh) * 2023-03-31 2025-11-21 三井化学株式会社 氨基甲酸酯化合物

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3201470A (en) 1965-08-17 Chsx c cech
US2916490A (en) 1959-12-08 Ocjhs
US2982783A (en) 1961-05-02 Amevoevdanes
US3123642A (en) 1964-03-03 Indanyl and tetrahydronaphthyl
SE371190B (enExample) 1972-03-24 1974-11-11 Kabi Ab
US2573645A (en) 1949-05-25 1951-10-30 Smith Kline French Lab N-hydroxyethyl aminoindanes
GB852735A (en) 1956-04-13 1960-11-02 Schering Ag Manufacture of 1-aminoindanes
US3060091A (en) 1961-02-13 1962-10-23 Ciba Geigy Corp Analgesic composition consisting of morphines and amino-indanes
US3178478A (en) 1961-02-13 1965-04-13 Ciba Geigy Corp 2-amino-5-halo-indanes
US3253037A (en) 1962-06-19 1966-05-24 Ciba Geigy Corp N-2-alkynyl-amino-benzocylo-alkanes
GB1187017A (en) 1966-07-16 1970-04-08 Aspro Nicholas Ltd Substituted 1-Amino Indanes and Tetrahydronaphthalens
US3709996A (en) 1963-08-02 1973-01-09 Aspro Nicholas Ltd Pharmaceutical compositions containing n-cyclopropyl-1-aminoindane compounds and adapted for administration to obtain inhibition of monoamine oxidase enzyme and process
NL6408165A (enExample) 1964-07-17 1966-01-18
US3308157A (en) 1964-08-07 1967-03-07 Colgate Palmolive Co N-(benzocyclobutene-1-loweralkyl)-carboxylic acid amides
US3637740A (en) 1969-04-21 1972-01-25 Pfizer Aminobenzocycloalkane compounds
US3507962A (en) 1969-05-09 1970-04-21 Thompson Chem Co Hayward Controlling leafminer insects with selected carbamate insecticides,including 3,5-dimethyl-4-dimethylamino-methyl phenyl-n-methylcarbamate
US3704323A (en) 1969-12-23 1972-11-28 Squibb & Sons Inc Indane derivatives
NL7011683A (enExample) 1970-08-07 1972-02-09
US3991207A (en) 1971-03-18 1976-11-09 Pfizer Inc. Combination therapy for Parkinson's disease
US3751420A (en) 1971-04-01 1973-08-07 Squibb & Sons Inc Monoolmonoene amines
BE786748A (fr) 1971-07-26 1973-01-26 Basf Ag 1-aminomethyl-indanes-n-substitues
US4029731A (en) 1974-11-06 1977-06-14 Pfizer Inc. Aminophenyltetralin compounds
US4134997A (en) 1977-03-01 1979-01-16 University Of Iowa Research Foundation Effect of an aminotetralin derivative on coronary blood flow in infarcted hearts
US4096173A (en) 1977-03-28 1978-06-20 Eli Lilly And Company Chlorinated 1-aminoindane N-methyl transferase inhibitors
US4128666A (en) 1977-08-18 1978-12-05 Smithkline Corporation 4 AND 5-Halo substituted 2-indanamine compounds
US4132737A (en) 1978-02-27 1979-01-02 Eli Lilly And Company Trifluoromethyl substituted 1-aminoindanes
US5286747A (en) 1981-05-08 1994-02-15 Per A. E. Carlsson 1-alkyl-2-aminotetralin derivatives
DE3407842A1 (de) 1983-03-04 1984-09-06 Otsuka Pharmaceutical Co. Ltd., Tokyo Indanderivate und deren salze, verfahren zu deren herstellung und arzneimittel und antioxidationsmittel, welche diese enthalten
US4529723A (en) 1983-04-29 1985-07-16 William H. Rorer, Inc. Bicyclic benzenoid aminoalkylene ethers and thioethers, pharmaceutical compositions and use
US5242919A (en) 1984-08-31 1993-09-07 Otsuka Pharmaceutical Co., Ltd. 2,3-dihydro-1H-indene derivatives
JPS6169747A (ja) 1984-08-31 1986-04-10 Otsuka Pharmaceut Co Ltd ２，３―ジヒドロ―１ｈ―インデン誘導体及びその製造法
US5378729A (en) 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5654301A (en) 1985-02-15 1997-08-05 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
IL74497A (en) 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
US4632939A (en) 1985-03-15 1986-12-30 Eli Lilly And Company Anticonvulsant agents
US4833273A (en) 1986-02-03 1989-05-23 Warner-Lambert Company Process for the resolution of 1-aminoindanes
DE252290T1 (de) 1986-06-10 1988-06-09 Chiesi Farmaceutici S.P.A., Parma Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
US5153225A (en) 1986-12-10 1992-10-06 Bayer Aktiengesellschaft Substituted basic 2-aminotetralin in pharmaceuticals
HU201906B (en) 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
US5011995A (en) 1987-07-28 1991-04-30 Ciba-Geigy Corporation Process for the preparation of optically active secondary amines
US4873241A (en) 1988-10-31 1989-10-10 Fisons Corporation 2-amino-N-(2-phenylindan-2-yl)acetamides useful as anti-epileptics
US5225596A (en) 1989-01-09 1993-07-06 The Upjohn Company Halo substituted aminotetralins
CA1335106C (en) 1989-02-27 1995-04-04 John Mehnert Schaus Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes
JP2725378B2 (ja) * 1989-05-29 1998-03-11 武田薬品工業株式会社 カルバミド酸エステル誘導体
IE902294A1 (en) 1989-07-06 1991-01-16 Abbott Lab Alkynyl amines that regulate cholinergic neurotransmission
US5118704A (en) 1989-08-30 1992-06-02 Whitby Research, Inc. Substituted 2-aminotetralins useful as dopaminergics
US5071875A (en) 1989-09-25 1991-12-10 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
FR2654104B1 (fr) 1989-11-07 1992-01-03 Adir Nouveaux derives du 1,2-benzisoxazole, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
JPH03176457A (ja) 1989-12-04 1991-07-31 Nippon Paint Co Ltd 新規プロパルギル化合物、その製法ならびに該化合物を含む被覆材
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
FR2662162B1 (fr) 1990-05-18 1995-01-20 Adir Nouveaux derives de l'amino piperidine, de l'amino pyrrolidine et de l'amino perhydroazepine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
TW197435B (enExample) 1990-11-22 1993-01-01 Takeda Pharm Industry Co Ltd
IL99759A (en) 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
PT664291E (pt) 1992-10-05 2000-11-30 Ube Industries Composto de pirimidina
US5350762A (en) 1993-03-08 1994-09-27 Hoechst-Roussel Pharmaceuticals Incorporated Tetrahydrocyclopent[B]indole methanamines and related compounds
GB9315600D0 (en) 1993-07-28 1993-09-08 Smithkline Beecham Plc Compounds
JP3342491B2 (ja) 1993-08-06 2002-11-11 ファルマシア・アンド・アップジョン・カンパニー 選択的ドーパミンｄ３リガンドとしての２−アミノインダン類
US5516943A (en) 1993-09-14 1996-05-14 Sepracor, Inc. Process for preparing cyclic CIS-1-amino-2-alkanols
US5401758A (en) 1993-10-07 1995-03-28 Bristol-Myers Squibb Company Pyridinyl cyanoguanidine compounds
IL111240A (en) 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
US5877218A (en) 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
HU225986B1 (en) * 1994-01-10 2008-02-28 Teva Pharma Use of 1-aminoindan derivatives for preparing pharmaceutical compns. and 1-aminoindan derivatives
FR2717175B1 (fr) 1994-03-11 1996-06-14 Adir Nouveaux composés alkylaminoindanes, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
IT1271679B (it) 1994-07-18 1997-06-04 Mediolanum Farmaceutici Srl Derivati del fenilcarbammato atti all'impiego come anticolinesterasici
US5646188A (en) 1995-07-05 1997-07-08 Teva Pharmaceutical Industries, Ltd. Polyamine derivatives of 1-aminoindan
ATE377585T1 (de) * 1996-12-18 2007-11-15 Teva Pharma Aminoindanderivate
US6251938B1 (en) 1996-12-18 2001-06-26 Teva Pharmaceutical Industries, Ltd., Phenylethylamine derivatives
JP3002155B2 (ja) 1997-06-25 2000-01-24 日本サーボ株式会社 景品懸吊装置
US20040010038A1 (en) 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors

Also Published As

Publication number Publication date
JP4222632B2 (ja) 2009-02-12
EP1535902B1 (en) 2007-11-07
US6303650B1 (en) 2001-10-16
CA2275425C (en) 2009-08-04
US6538025B2 (en) 2003-03-25
CA2275425A1 (en) 1998-06-25
PT966435E (pt) 2005-06-30
DE69738275D1 (de) 2007-12-20
DE69732984D1 (de) 2005-05-12
WO1998027055A1 (en) 1998-06-25
DK0966435T3 (da) 2005-08-15
EP1535902A1 (en) 2005-06-01
IL130528A (en) 2004-12-15
ATE377585T1 (de) 2007-11-15
USRE39616E1 (en) 2007-05-08
HK1024462A1 (en) 2000-10-13
HU229507B1 (en) 2014-01-28
JP2001506269A (ja) 2001-05-15
EP0966435B1 (en) 2005-04-06
AU5726898A (en) 1998-07-15
HK1076098A1 (en) 2006-01-06
US20020188020A1 (en) 2002-12-12
ES2241064T3 (es) 2005-10-16
US6462222B1 (en) 2002-10-08
HUP0101130A3 (en) 2003-02-28
HUP0101130A2 (hu) 2001-08-28
DE69738275T2 (de) 2008-08-28
EP0966435A1 (en) 1999-12-29
ATE292619T1 (de) 2005-04-15
EP0966435A4 (en) 2003-04-16

Similar Documents

Publication Publication Date Title
DE69732984T2 (de) Aminoindanderivate
DE69736066T2 (de) Pharmazeutische zusammensetzungen enthaltend s-(-)-n-propargyl-1-aminoindan
DE69434178T2 (de) R-enantiomer des n-propargyl-1-aminoindan zur behandlung verschiedener krankheiten und mesylat, esylat und sulfat davon
DE69535315T2 (de) 1-aminoindanderivate und zusammensetzungen hiervon
DE69218101T2 (de) Monofluorierte Derivate von N-Propargyl-1-Aminoindan und deren Verwendung als Monoamino-Oxidaseinhibitoren
DE69613240T2 (de) N-aminoalkylfluorencarboxamide, neue klasse von dopaminerezeptor subtype spezifische liganden
DE69615668T2 (de) O-carbamoyl-(d)-phenylalanilolverbindungen und verfahren zu ihrer herstellung.
US6251938B1 (en) Phenylethylamine derivatives
DE19837627A1 (de) Neue Aminosäureester von Arylsulfonamiden und Analoga
EP1694318A1 (de) (s)-2-n-propylamino-5-hydroxytetralin als d3-agonistisches therapeutikum
DE68917499T2 (de) Catechol-Derivate und sie enthaltende pharmazeutische Präparate.
DE602005004142T2 (de) 4-hydroxy-4-methylpiperidin-1-carbonsäure-(4-methoxy-7-morpholin-4-ylbenzothiazol-2-yl)-amid
DE69813228T2 (de) Alifatische propargylamine als zelluläres rettungsmittel
DE60315973T2 (de) Hydroxy-tetrahydro-naphthalinylharnstoff-derivate
EP0726265B1 (de) Antineurodegenerativ wirksame 10-Aminoaliphatyl-dibenz- b,f oxepine
EP1519726B1 (de) Heteroarencarboxamide zur verwendung als dopamin-d3 liganden zur behandlung von zns-erkrankungen
DE69725467T2 (de) Phenylethylamin-derivate
DE69514533T2 (de) Kondensierte indole und chinoxalinderivate, ihre herstellung und verwendung als glutamatantagonisten
DE60124148T2 (de) Kalzilytische verbindungen
EP0491263A1 (de) Phenylalkylaminoalkyl-Verbindungen sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE69426581T2 (de) Isatinoxim-Derivate, ihre Herstellung und Verwendung
DE69916663T2 (de) Tetrahydroisochinolinalkanol-derivate und diese enthaltende pharmazeutische zubereitungen
DE60105221T2 (de) Verfahren zur Herstellung vom Mesylat Salz des Trihydrats des 1-(4-Hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanols und Zwischenprodukte für dieses Verfahren
CH625207A5 (en) Process for the preparation of novel guanidine derivatives
AT392783B (de) Neue n-substituierte 3-piperidin- oder 3-tetrahydropyridincarbonsaeuren und derivate

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD, IL

Owner name: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEB, IL